Of those surveyed in rural communities, 43 percent intended to perform self-exam but did not follow through.
Behavioral intervention had no impact on time to progression among men with early-stage disease.
Ambulatory oncology care settings include outpatient centers for chemotherapy infusion and the administration of radiation therapy.
Long-term follow-up of the Radiation Therapy Oncology Group 0617 trial continues to support a 60-Gy radiation therapy dose as the standard of care.
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
In a study, localized prostate cancer patients reported clinically meaningful differences in urinary, bowel, sexual, and hormonal function by management option up to 5 years of follow-up.
Researchers suggested several criteria for determining drug value in a survey given to participants for feedback.
Lorcaserin may potentially increase the risk of cancer, according to results from a clinical trial assessing the safety of the weight loss agent.
Pelvic physical therapy may be more appropriate than Kegel exercises in managing post-radical prostatectomy pain and stress urinary incontinence, according to a new study.
Currently, splenomegaly is not included as a prognostic factor in major prognostic models of Philadelphia-negative myeloproliferative neoplasms.
AUCs were 0.997, 0.986 for distinguishing between benign, malignant biopsy cores, respectively.
Incidence up for all cancer sites combined and for prostate cancer, thyroid cancer, leukemia.
Toxicity profile and readmission rates among patients who underwent radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab are in line with previously published series reporting 90-day outcomes after RC with or without neoadjuvant chemotherapy.
The study’s primary endpoint was efficacy, determined by complete remission, peripheral blood cell count remission, quality of life, and JAK2 V617F allele burden.
The FDA has granted Orphan Drug designation to avatrombopag for the potential treatment of chemotherapy-induced thrombocytopenia, a complication that may lead to chemotherapy dose delays and regimen changes.